Strides Provides Updates As USFDA Requests All Manufacturers To Withdraw Ranitidine Products From The US Market

Strides Pharma Science Limited (Strides or the Company) today informed that US Food and Drug Administration (USFDA or the Agency) on April 1, 2020, has published a statement1 and issued letters to all manufacturers of Ranitidine across dosage forms requesting withdrawal of all prescription(Rx) and over-the-counter (OTC) ranitidine drugs from the market immediately. This latest step is based on their ongoing investigation of the N-Nitrosodimethylamine (NDMA) impurity in ranitidine medications. The USFDA’s statement, though, points out, “we didn’t observe unacceptable levels of NDMA in many of the samples that we tested”, but results indicate that NDMA levels may increase over time or when exposed to high temperatures.

Shares of Strides Pharma Science Ltd was last trading in BSE at Rs.326.3 as compared to the previous close of Rs. 322.55. The total number of shares traded during the day was 67947 in over 2625 trades.

The stock hit an intraday high of Rs. 350.8 and intraday low of 318.85. The net turnover during the day was Rs. 22476060.-Equity Bulls